Company Overview and News
KUALA LUMPUR (Oct 3): QL Resources Bhd shares rose as much as 21 sen or 3% to record high at RM7.08 so far today, after Kenanga Investment Bank Bhd raised its target price (TP) for the egg producer's shares to RM5. At 4:06pm, QL shares pared gains at RM7.02 among Bursa Malaysia top gainers. QL saw 2.57 million shares traded.
7084 BSMAF 1818
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899
KUALA LUMPUR (Sept 26): The FBM KLCI clawed back to erase its earlier losses at the midday break today, powered by gains at Tenaga Nasional Bhd and other select index-linked blue chips.
7084 7060 7036 0083 BATS 4162 7765 1163 5256 9334 5199 0154 KLKBY 5029 2445 5347 5258 3026 7216 TNABY 2836 TNABF HIPEF 1929
QL Resources Bhd (Sept 24, RM6.34) Maintain neutral with an unchanged target price (TP) of RM4.68: We recently visited one of QL Resources Bhd’s marine product manufacturing (MPM) plants in Hutan Melintang, Perak, operated by its subsidiary, QL Foods Sdn Bhd. The MPM division contributed 27.7% and 48.6% of the group’s revenue and profit before tax (PBT) respectively for the financial year ended March 31, 2018 (FY18), while Hutan Melintang plants contribute more than 30% (around RM300 million) of the MPM division’s revenue and 35% of QL’s overall MPM segment capacity.
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.41% in early trade this morning, tracking gains at most regional markets, lifted by select index-linked blue chips.
7084 BATS 4162 5014 6033 5139 PNADF 5347 0900 TNABY MYPRY 2836 TNABF PNAGF
KUALA LUMPUR (Sept 18): RHB Retail Research said QL Resources Bhd may climb higher after posting a white candle and hitting its new 52-week high.
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...